Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
pomalidomide, Quantity: 2 mg
Juno Pharmaceuticals Pty Ltd
Capsule, hard
Excipient Ingredients: pregelatinised starch; sodium stearylfumarate; croscarmellose sodium; mannitol; titanium dioxide; indigo carmine; purified water; iron oxide yellow; erythrosine; Gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; Shellac; ethanol absolute; ammonia; potassium hydroxide
Oral
21 capsules, 14 capsules
(S4) Prescription Only Medicine
Pomalidomide, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.,Pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Visual Identification: Size 2 hard gelatin capsules with dark blue cap and an orange body printed with 'NAT' in white ink on the cap and '2 mg' in white ink on the body of the capsules.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2021-05-18